Sign up to receive the latest news and updates from NervGen
Latest News


NervGen Pharma Responds to Recent Increase in Market Activity


NervGen Pharma Appoints Paul Brennan as President & Chief Executive Officer / Lloyd Mackenzie Appointed to the New Position of Chief Operating Officer
Latest Financial Results
Q3 2019

Quarter Ended September 30, 2019

Financial Statements
Balance Sheet
Income Statement
Cash Flow

Investor Relations

NervGen Pharma Corp.

Huitt Tracey

Corporate Communications


Canada: TSX.V  Symbol "NGEN"

US: OTCQX       Symbol "NGENF"

Transfer Agent

Computershare Investor
Services Inc.
510 Burrard Street, 3rd Floor
Vancouver, BC V6C 3B9

T: (604) 661-9400

CUSIP#: 64082X203

ISIN #    CA64082X2032

© 2019



Website last updated January 31, 2020. The information posted was accurate at the time of posting, but may be superseded by subsequent disclosures.  

This website may include predictions, estimates or other information that might be considered forward-looking. While these forward-looking statements represent our current judgment on what the future holds, they are subject to risks and uncertainties that could cause actual results to differ materially. You are cautioned not to place undue reliance on these forward-looking statements. Please keep in mind that we are not obligating ourselves to revise or publicly release the results of any revision to these forward looking statements in light of new information or future events. You should also review our most recent filings on SEDAR ( for a more complete discussion of these factors and other risks, particularly under the heading “Risk Factors.”